drugset / Trial / NCT02575456
A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine
Phase 2
Completed
500 enrolled
Jiangsu Province Centers for Disease Control and Prevention
Beijing Institute of Biotechnology · collabTianjin Cansino Biotechnology Inc · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults Aged Between 18 and 50 years in Sierra Leone.
Timeline
- Start
- 2015-10
- Primary completion
- 2016-06
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad5-EBOV | Vaccine | 8e+10 unknown | Intramuscular |
| Subject | Ad5-EBOV | Vaccine | 1.6e+11 unknown | Intramuscular |